The authors documented that although p53 is an important target protein for SIRT1 action, the selective inhibitor of this deacetylase—EX527 significantly suppressed the proliferation and cisplatin resistance of three endometrial carcinoma cell lines regardless of the p53 mutation status. Here, TP53 is linked to endometrial carcinoma.